GeneDx Tops Q3 2026 Estimates as Revenue Rises 5.4% to $123.1M

GeneDx (WGS) topped estimates for the third quarter of 2026. Revenue was $123.1 million, up 5.4% from a year earlier, in line with the $122.9 million estimate, and adjusted EPS was $0.28, down 43% from a year earlier, above the $0.07 estimate.

Shares fell 3.0% in after-hours trading as of 4:07 p.m. ET, to $63.73 from a $65.72 close.

Q3 2026 scorecard

By our calculation, adjusted EPS was $0.21 above it. The QoQ column compares with the previous quarter's revenue of $114.4 million and adjusted EPS of $0.01. The YoY column compares with $116.7 million and $0.49 in the same quarter a year earlier.

Track record

• EPS record. Adjusted EPS beat the estimate in 7 of the last 8 reports, including this one.
• Revenue record. Revenue beat the estimate in 5 of the last 8 reports.
• Revenue trend. Revenue over the last 5 reports, oldest first: $116.7 million, $121.0 million, $102.3 million, $114.4 million and $123.1 million.

What to watch

• Next-quarter estimates. Consensus calls for EPS of $0.29 and revenue of $142.6 million next quarter, based on 4 analysts.
• Revenue growth. Whether revenue keeps growing from a year earlier after this quarter's 5.4% increase to $123.1 million.
• Estimate record. Whether GeneDx extends a record of beating EPS estimates in 7 of its last 8 reports.
• Related coverage. See our reports on WEBTOON Entertainment, Take-Two Interactive Software, Life360 and Ameresco.

Sources: Results are from GeneDx's Nov. 9, 2026 quarterly report. Estimates are consensus figures. The prior-quarter and year-ago comparison figures are from GeneDx's earlier quarterly reports. Items labeled by our calculation are our own arithmetic. This article is informational only and is not investment advice.